title: Rituximab for post-transplant recurrences of FSGS.
abstract: A 14-yr-old boy whose primary kidney disease was FSGS developed severe recurrence of proteinuria immediately after a second living-related kidney transplant. Despite pre- and post-operative PP and immunosuppressive treatment consisting of steroids, CycA, daclizumab, and MMF, daily protein excretion and serum creatinine increased. We therefore administered rituximab on the fourth day of transplantation. He received four weekly doses of rituximab (375 mg/m(2)/dose), which resulted in a rapid clearing of circulating CD19-positive B cells, and remission of proteinuria was achieved six wk after the first rituximab treatment. Graft function was excellent six months after transplantation with proteinuria of 8 mg/m(2)/h. We conclude that rituximab may be an effective treatment for post-transplant recurrence of FSGS.
authors.affiliation: Department of Pediatric Nephrology, Baskent University Faculty of Medicine, Ankara, Turkey.
authors.forename: Umut Selda
authors.initials: US
authors.lastname: Bayrakci
authors.forename: Esra
authors.initials: E
authors.lastname: Baskin
authors.forename: Hale
authors.initials: H
authors.lastname: Sakalli
authors.forename: Hamdi
authors.initials: H
authors.lastname: Karakayali
authors.forename: Mehmet
authors.initials: M
authors.lastname: Haberal
mesh_terms: D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D001706:Biopsy; D016207:Cytokines / Q000378:metabolism; D005923:Glomerulosclerosis, Focal Segmental / Q000188:drug therapy* / Q000209:etiology*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000379:methods*; D008297:Male; D011507:Proteinuria / Q000188:drug therapy; D012008:Recurrence; D012074:Remission Induction; D000069283:Rituximab; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D016207:Cytokines; D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D000069283:Rituximab